CORT - コ―セプト・セラピュ―ティクス (Corcept Therapeutics Incorporated) コ―セプト・セラピュ―ティクス

 CORTのチャート


 CORTの企業情報

symbol CORT
会社名 Corcept Therapeutics Inc (コ―セプト・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 コーセプト・セラピューティクス(Corcept Therapeutics Incorporated)は重篤な代謝と精神・腫瘍疾患の治療薬の発見・開発・商業化に従事する製薬会社である。同社はグルココルチコイド受容体(GR)においてアンタゴニストとして作用することによりコルチゾールの効果を調節する化合物であるミフェプリストンを開発する。同社は選択的コルチゾールモジュレーターであるCORT125134の2つの臨床試験を実施する。同社はクッシング症候群患者の治療法として、CORT125134を検討する。第2の試験では、固形腫瘍がん患者を治療するためのCORT125134とナブパクリタキセルの組み合わせが検討される。   コ―セプト・セラピュ―ティクスは米国の製薬会社。代謝異常、精神疾患、がん細胞などの治療薬の開発と商品化に従事。主要製品はクッシング病を患う成人の高血糖症治療薬「Korlym」。また、心因性うつ病治療薬として「Korlym」の有効成分であるミフェプリストンの開発も進める。   Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
本社所在地 149 Commonwealth Drive Menlo Park CA 94025 USA
代表者氏名 James N. Wilson ジェームズ・N・ウィルソン
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-327-3270
設立年月日 35916
市場名 NASDAQ Small Cap
ipoyear 1982年
従業員数 136人
url www.corcept.com
nasdaq_url https://www.nasdaq.com/symbol/cort
adr_tso
EBITDA EBITDA(百万ドル) 77.13800
終値(lastsale) 13.295
時価総額(marketcap) 1542901262.39
時価総額 時価総額(百万ドル) 1591.063
売上高 売上高(百万ドル) 216.01400
企業価値(EV) 企業価値(EV)(百万ドル) 1431.118
当期純利益 当期純利益(百万ドル) 180.97500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Corcept Therapeutics Incorporated revenues increased 90% to $120M. Net income increased from $17M to $35.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from $0.15 to $0.31.

 CORTのテクニカル分析


 CORTのニュース

   The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax  2020/09/03 11:55:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) (announced potent SARS-CoV-2 neutralizing data from COVID-19 therapeutic antibody program) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 2) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (priced a $9.6-million follow-on offering) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Entera Bio Ltd (NASDAQ: ENTX ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Interpace Biosciences Inc (NASDAQ: IDXG ) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Nkarta Inc (NASDAQ: NKTX ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Psychemedics Corp. (NASDAQ: PMD ) Rockwell Medical Inc (NASDAQ: RMTI ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Sutro To Present Positive Phase 1 Ovarian Cancer Data In an abstract submitted to the International Gynecologic Cancer Society …
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?  2020/06/03 15:30:39 Zacks Investment Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?  2020/06/03 15:30:09 Zacks Investment Research
Is (CORT) Outperforming Other Medical Stocks This Year?
   Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y  2020/05/05 18:50:00 Zacks Investment Research
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?  2020/06/03 15:30:39 Zacks Investment Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?  2020/06/03 15:30:09 Zacks Investment Research
Is (CORT) Outperforming Other Medical Stocks This Year?
   Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y  2020/05/05 18:50:00 Zacks Investment Research
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
   Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates  2020/05/04 23:05:06 Zacks Investment Research
Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?  2020/06/03 15:30:39 Zacks Investment Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?  2020/06/03 15:30:09 Zacks Investment Research
Is (CORT) Outperforming Other Medical Stocks This Year?
   Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y  2020/05/05 18:50:00 Zacks Investment Research
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
   Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates  2020/05/04 23:05:06 Zacks Investment Research
Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

 関連キーワード  (医薬品 米国株 コ―セプト・セラピュ―ティクス CORT Corcept Therapeutics Incorporated)

 twitter  (公式ツイッターやCEOツイッターなど)